SHINE Medical Technologies announced recently that it closed a $50 million financing round with Oaktree Capital Management.

According to a release, the funds will be for the construction of SHINE’s medical isotope production facility and its commercialization of diagnostic and therapeutic isotopes.

“We are excited to welcome Oaktree to SHINE’s growing list of top-tier institutional investors,” CEO Greg Piefer said in a statement. “Oaktree has broad expertise in complex infrastructure projects like our medical isotope facility.”

SHINE’s facility is expected to be completed in 2021, and isotope production will begin the following year.

Oaktree Capital Management is headquartered in Los Angeles.